Strikingly, this IL-2 mutant exhibited distinct effects on the phenotype of expanded Tregs and had better efficacy than its WT counterpart in ameliorating disease severity in murine disease models of SLE and GvHD. This evidence concerns the gene IL2 and graft versus host disease.